{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:55:05Z","timestamp":1781506505220,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,14]]},"DOI":"10.7759\/cureus.110861","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:41:46Z","timestamp":1781505706000},"source":"Crossref","is-referenced-by-count":0,"title":["Fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography (FDG PET\/CT) Monitoring of Rapidly Progressive Low-Risk Cutaneous Melanoma: A Case Report of Durable Response to Combined Stereotactic Body Radiotherapy (SBRT) and Immunotherapy"],"prefix":"10.7759","author":[{"given":"Jelena","family":"Pantovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Kotur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Strahinja","family":"Odalovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Petkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Pantic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Sobic Saranovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Artiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana","family":"Seha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17162648","article-title":"Confronting melanoma radioresistance: mechanisms and therapeutic strategies","volume":"17","author":"Gorodetska I","year":"2025","unstructured":"Gorodetska I, Schulz A, Behre G, Dubrovska A. Confronting melanoma radioresistance: mechanisms and therapeutic strategies. Cancers (Basel). 2025, 17:2648. 10.3390\/cancers17162648","journal-title":"Cancers (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.sult.2014.02.001","article-title":"Metastatic melanoma in the chest and abdomen: the great radiologic imitator","volume":"35","author":"Chang ST","year":"2014","unstructured":"Chang ST, Desser TS, Gayer G, Menias CO. Metastatic melanoma in the chest and abdomen: the great radiologic imitator. Semin Ultrasound CT MR. 2014, 35:272-89. 10.1053\/j.sult.2014.02.001","journal-title":"Semin Ultrasound CT MR"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2025.501212","article-title":"Predictive factors for distant metastasis in early cutaneous melanoma: a 20-year experience of a Turkish tertiary referral hospital","volume":"100","author":"Ozbagcivan O","year":"2025","unstructured":"Ozbagcivan O, Kazaz E. Predictive factors for distant metastasis in early cutaneous melanoma: a 20-year experience of a Turkish tertiary referral hospital. An Bras Dermatol. 2025, 100:501212. 10.1016\/j.abd.2025.501212","journal-title":"An Bras Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010101","article-title":"Predictive factors in metastatic melanoma treated with immune checkpoint inhibitors: from clinical practice to future perspective","volume":"16","author":"Poletto S","year":"2023","unstructured":"Poletto S, Paruzzo L, Nepote A, Caravelli D, Sangiolo D, Carnevale-Schianca F. Predictive factors in metastatic melanoma treated with immune checkpoint inhibitors: from clinical practice to future perspective. Cancers (Basel). 2023, 16:101. 10.3390\/cancers16010101","journal-title":"Cancers (Basel)"},{"key":"ref5","article-title":"Survival rates of patients with metastatic malignant melanoma","volume":"7","author":"Sandru A","year":"2014","unstructured":"Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. J Med Life. 2014, 7:572-6.","journal-title":"J Med Life"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164026","article-title":"BRAF mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers","volume":"15","author":"Castellani G","year":"2023","unstructured":"Castellani G, Buccarelli M, Arasi MB, et al.. BRAF mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers. Cancers (Basel). 2023, 15:4026. 10.3390\/cancers15164026","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3529-5","article-title":"Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care","volume":"17","author":"Heppt MV","year":"2017","unstructured":"Heppt MV, Siepmann T, Engel J, et al.. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. BMC Cancer. 2017, 17:536. 10.1186\/s12885-017-3529-5","journal-title":"BMC Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000832","article-title":"Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors","volume":"32","author":"Ismail RK","year":"2022","unstructured":"Ismail RK, Suijkerbuijk KP, de Boer A, et al.. Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors. Melanoma Res. 2022, 32:460-8. 10.1097\/CMR.0000000000000832","journal-title":"Melanoma Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000818","article-title":"Recent advances in radiosensitivity determinants in melanoma","volume":"34","author":"Krayem M","year":"2022","unstructured":"Krayem M, Ghanem GE, Van Gestel D. Recent advances in radiosensitivity determinants in melanoma. Curr Opin Oncol. 2022, 34:131-8. 10.1097\/CCO.0000000000000818","journal-title":"Curr Opin Oncol"},{"key":"ref10","article-title":"Radiation therapy for melanoma","author":"Shi W","year":"2017","unstructured":"Shi W. Radiation therapy for melanoma. Cutaneous Melanoma: Etiology and Therapy. Codon Publications, Brisbane, AU; 2017."},{"key":"ref11","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae). melanoma: cutaneous. (2025). Accessed: March 15, 2026: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1492."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care","volume":"18","author":"Keung EZ","year":"2018","unstructured":"Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018, 18:775-84. 10.1080\/14737140.2018.1489246","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold M","year":"2022","unstructured":"Arnold M, Singh D, Laversanne M, et al.. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 2022, 158:495-503. 10.1001\/jamadermatol.2022.0160","journal-title":"JAMA Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00795-3","article-title":"Global incidence, mortality, risk factors and trends of melanoma: a systematic analysis of registries","volume":"24","author":"Huang J","year":"2023","unstructured":"Huang J, Chan SC, Ko S, et al.. Global incidence, mortality, risk factors and trends of melanoma: a systematic analysis of registries. Am J Clin Dermatol. 2023, 24:965-75. 10.1007\/s40257-023-00795-3","journal-title":"Am J Clin Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01289-x","article-title":"Surgical management of melanoma: advances and updates","volume":"24","author":"Santamaria-Barria JA","year":"2022","unstructured":"Santamaria-Barria JA, Mammen JM. Surgical management of melanoma: advances and updates. Curr Oncol Rep. 2022, 24:1425-32. 10.1007\/s11912-022-01289-x","journal-title":"Curr Oncol Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041106","article-title":"Immunotherapy in melanoma: recent advances and future directions","volume":"15","author":"Knight A","year":"2023","unstructured":"Knight A, Karapetyan L, Kirkwood JM. Immunotherapy in melanoma: recent advances and future directions. Cancers (Basel). 2023, 15:1106. 10.3390\/cancers15041106","journal-title":"Cancers (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.69","article-title":"BRAF targeted therapy changes the treatment paradigm in melanoma","volume":"8","author":"Ribas A","year":"2011","unstructured":"Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol. 2011, 8:426-33. 10.1038\/nrclinonc.2011.69","journal-title":"Nat Rev Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1467098","article-title":"Research on the influence of radiotherapy-related genes on immune infiltration, immunotherapy response and prognosis in melanoma based on multi-omics","volume":"15","author":"Shi Y","year":"2024","unstructured":"Shi Y, Zhao W, Ding Y, Ge X, Ju M. Research on the influence of radiotherapy-related genes on immune infiltration, immunotherapy response and prognosis in melanoma based on multi-omics. Front Immunol. 2024, 15:1467098. 10.3389\/fimmu.2024.1467098","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21239324","article-title":"Immunostimulatory effects of radiotherapy for local and systemic control of melanoma: a review","volume":"21","author":"Takahashi J","year":"2020","unstructured":"Takahashi J, Nagasawa S. Immunostimulatory effects of radiotherapy for local and systemic control of melanoma: a review. Int J Mol Sci. 2020, 21:9324. 10.3390\/ijms21239324","journal-title":"Int J Mol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/499921-fluorodeoxyglucose-positron-emission-tomographycomputed-tomography-fdg-petct-monitoring-of-rapidly-progressive-low-risk-cutaneous-melanoma-a-case-report-of-durable-response-to-combined-stereotactic-body-radiotherapy-sbrt-and-immunotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:41:58Z","timestamp":1781505718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/499921-fluorodeoxyglucose-positron-emission-tomographycomputed-tomography-fdg-petct-monitoring-of-rapidly-progressive-low-risk-cutaneous-melanoma-a-case-report-of-durable-response-to-combined-stereotactic-body-radiotherapy-sbrt-and-immunotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,14]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.110861","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,14]]}}}